Recent Updates
Recently added Catalysts

GTN

Phase 1

Patients With Pace Makers But no Evidence of Ischemic Heart Disease | Small molecule | Cardiovascular |Pfizer, Inc.|Last Updated: Nov 8, 2006

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedUNCONTROLLED
Total Trials1
Total Enrollment36

FDA Designations

No designations recorded

Clinical trial landscape

GTN · 1 trial · 1 indication

Phase 1 1
NCT00174512A Methodological Open Label Cross-Over Controlled Study To Assess The Effect Of Drugs On Ventricular Repolarization and QT Interval At Fixed Heart Rate Under Autonomic BlockadePatients With Pace Makers But no Evidence of Ischemic Heart Disease
COMPLETED36 Analytics
PHASE1COMPLETED
A Methodological Open Label Cross-Over Controlled Study To Assess The Effect Of Drugs On Ventricular Repolarization and QT Interval At Fixed Heart Rate Under Autonomic Blockade
Patients With Pace Makers But no Evidence of Ischemic Heart Disease
NCT0017451236
Unlock trial analytics

Study Endpoints

Primary Endpoints

QT and QTc changes at two different pacing rates in atrially paced patients

Secondary Endpoints

Change in QT and QTcF before and after Moxifloxacin with and without autonomic blockade at each pacing rate Change in QT and QTcF before and after autonomic blockade at each pacing rate
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeECT

Interventions

NameTypeDescription
GTNDRUG -
MoxifloxacinDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites6

Inclusion Criteria: * Patients with pace-makers but otherwise normal ventricular function Exclusion Criteria: * Nitrates, beta blockers

Countries:BelgiumUnited Kingdom
Unlock Eligibility Criteria

Frequently asked questions about GTN

What is GTN used for?

GTN is a small molecule being studied for use in patients with pace makers but no evidence of ischemic heart disease. It is in Phase 1 clinical development for this cardiovascular indication. The drug is being investigated to assess its effect on ventricular repolarization and the QT interval at a fixed heart rate under autonomic blockade.

Who makes GTN?

GTN is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development for a cardiovascular indication involving patients with pace makers but no evidence of ischemic heart disease.

What phase is GTN in?

GTN is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed, with a total enrollment of 36 participants. The trial was a methodological open-label, cross-over, controlled study.

What clinical trials is GTN in?

GTN has one completed clinical trial registered under NCT00174512. The trial was a Phase 1, methodological, open-label, cross-over, controlled study to assess the effect of drugs on ventricular repolarization and the QT interval at a fixed heart rate under autonomic blockade. It enrolled 36 participants in Belgium and the United Kingdom.

Is GTN the same as nitroglycerin?

GTN is a common abbreviation for glyceryl trinitrate, also known as nitroglycerin. In this context, GTN is being studied by Pfizer, Inc. for its effects on ventricular repolarization and the QT interval in patients with pace makers but no evidence of ischemic heart disease. The drug is in Phase 1 clinical development.